Novo Nordisk has filed a federal lawsuit against Eli Lilly, alleging that advertisements for Zepbound and Mounjaro are deceptively false. Novo claims Lilly used outdated clinical trial data by comparing its highest doses to lower doses of Wegovy and Ozempic while ignoring newer, higher-dose versions of Novo's products. Eli Lilly denies the allegations, stating its ads are truthful and based on the SURMOUNT-5 head-to-head trial. Novo Nordisk is seeking a court order to withdraw the ads, corrective advertising, and financial damages.
Editor's Analysis
Missing perspectives include the viewpoints of healthcare providers and patients regarding how these comparative advertisements influence treatment choices. There is also a lack of independent medical or regulatory analysis on whether the SURMOUNT-5 trial data was used deceptively.